ImmunityBio (NASDAQ:IBRX) experienced a sharp rise in its stock price on Friday, climbing 9.2% to $8.51. The move pushed the company's market capitalization to $8.74 billion, significantly above the $5.7 billion threshold used by FTSE Russell to separate the large-cap Russell 1000 from the small-cap Russell 2000 index. This discrepancy drew investor attention as the annual index reconstitution is set to finalize after the market close on Friday, with updated indexes taking effect at the start of trading on Monday.
Trading volume was heavy, with approximately 17 million shares changing hands, as market participants positioned themselves for potential demand from index-tracking funds. Despite the surge, the company did not release any new filings to explain the price movement, with the most recent SEC filing dated June 10.
The Russell U.S. index reconstitution is a major event, with about $12.2 trillion in assets benchmarked to or invested in products tracking these indexes, according to FTSE Russell. At the June 2025 reconstitution, $217.2 billion traded at the close, highlighting the scale of rebalancing activity. Catherine Yoshimoto, director of product management at FTSE Russell, noted in a May note that the event is typically one of the highest trading volume days of the year, with technology and industrial stocks leading moves into the Russell 1000. Health-care stocks, however, accounted for a smaller share.
ImmunityBio's market cap, which is roughly 53% above the $5.7 billion cutoff, underscores the stock's elevated valuation relative to its financial metrics. The company's market cap is approximately 49 times its annualized first-quarter product revenue of $44.2 million. While net product revenue grew 168% year-over-year and 15% sequentially, the company reported an adjusted net loss of $86.2 million for the quarter. Cash and marketable securities stood at $380.9 million.
Chief Executive Richard Adcock highlighted strong demand for the company's product, ANKTIVA, and noted a solid cash position entering the second quarter. Founder Patrick Soon-Shiong revealed that a pivotal trial for BCG-naïve NMIBC had completed enrollment, supporting a planned sBLA filing in 2026. However, the company faces regulatory hurdles. In March, the FDA issued a warning letter stating that ANKTIVA's promotional materials were false or misleading, ordering the company to pull its TV ad and podcast.
Piper Sandler analyst Edward Tenthoff expressed confidence that ImmunityBio can comply with the FDA's requests and maintained his ANKTIVA revenue estimate. The company burned through $75.4 million in operating cash during the quarter but offset this with $223.9 million from financing activities.
The index rebalancing effect, while providing a short-term catalyst, does not guarantee ImmunityBio's inclusion in the Russell 1000, as the rank cutoff was based on April 30 data. Nonetheless, the price action reflects market expectations of continued demand from passive funds. Investors will be watching for further developments in the company's regulatory and commercial progress.
